US WorlMeds' Iwilfin Receives the US FDA's Approval for the Treatment of Children with Neuroblastoma
Shots:
- The approval was based on the clinical evaluation of Iwilfin (192mg, oral, BID) as maintenance therapy following SoC treatment, including immunotx. vs external control in children with high-risk neuroblastoma
- The results from the study depicted an improved EFS & OS whereas in 4yrs. following immunotx., the EFS was 84% vs 73%, 96% vs 84% of patients were alive thereby depicting a reduction in risk of relapse & death by 52% & 68%
- On further analysis the confirmatory results depicted a reduction in risk of relapse & death by 57%-41% & 71%-55%. Additionally, US WorldMeds partnered with the Beat Childhood Cancer Research Consortium to conduct the preclinical & clinical evaluation of Iwilfin
Ref: US WorlMeds | Image: US WorlMeds
Related News:- Ascentage Pharma's Alrizomadlin (APG-115) Receives the US FDA’s Rare Pediatric Disease Designation for the Treatment of Neuroblastoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
